Biotech groups slam Malaysia, Canada and Korea in Special 301 comments
20-02-2018
godfather744431 / iStockphoto.com
Supranational organisations such as the World Health Organization (WHO) and the United Nations Development Program (UNDP) are promoting acts, policies and practices that prevent biopharmaceutical innovators from securing and maintaining patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PhRMA, USTR, innovation, patent, Special 301 Report, medicines, IP protection, market access, barriers, biopharmaceutical
